These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Evaluation of the in-vitro antibacterial activity of Sch 34343.
    Author: Adam C, Naples L, Weiss W, Sabatelli F, Hare R, Loebenberg D, Miller GH.
    Journal: J Antimicrob Chemother; 1985 Jun; 15 Suppl C():39-56. PubMed ID: 3875604.
    Abstract:
    The in-vitro activity (as measured by geometric mean MICs, mg/l) of Sch 34343 against aerobic and anaerobic bacteria was compared with that of 14 other selected beta-lactam antibiotics including aztreonam, latamoxef (moxalactam), ceftazidime and imipenem. Sch 34343 had good activity (less than 2 mg/l) against most Gram-negative aerobic bacteria whether or not they contained high levels of plasmid-mediated or chromosomally-mediated beta-lactamases. It was slightly less potent against strains of Morganella and Serratia (less than 4 mg/l) and inactive against Pseudomonas (greater than 64 mg/l). A very small inoculum effect was observed against strains containing beta-lactamases indicating stability. Unlike the third-generation cephalosporins, Sch 34343 had excellent activity (less than or equal to 0.18 mg/l) against staphylococci, comparable to that of imipenem and ampicillin. While Sch 34343 had equally good potency (0.17 mg/l) against penicillinase-positive staphylococci, it was inactive against methicillin-resistant staphylococci (greater than or equal to 35 mg/l). Sch 34343 also had good activity against streptococci. The most unusual aspect of the in-vitro activity was its activity against Bacteroides (including Bact. fragilis) and other anaerobes. Sch 34343 had mean MICs less than or equal to mg/l for all Bacteroides and Clostridium spp. tested except CI. difficile (3.4 mg/l).
    [Abstract] [Full Text] [Related] [New Search]